BELLUS Health Inc. (BLU)

$14.745

+0.01 (+0.03%)
Rating:
Recommendation:
-
Symbol BLU
Price $14.745
Beta -0.279
Volume Avg. 5.38M
Market Cap 1.870B
Shares () -
52 Week Range 6.38-14.76
1y Target Est -
DCF Unlevered BLU DCF ->
DCF Levered BLU LDCF ->
ROE -24.27% Sell
ROA -22.87% Sell
Operating Margin -
Debt / Equity 0.33% Neutral
P/E -20.20 Strong Sell
P/B 5.06 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BLU news


Mr. Roberto Francesco Bellini
Healthcare
Biotechnology
NASDAQ Global Select

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.